On 22nd March members of the UKAR Steering Committee hosted our first Industry Engagement meeting to discuss plans for the registry with industry partners.
Industry partners from Menarini, Pfizer and Shionogi joined the meeting, along with colleagues from the National Institute for Healthcare Research (NIHR) Infectious Diseases National Specialty Group.
The University of Aberdeen team presented an overview of registries and plans for UKAR, both the initial database-type registry and ambitions for a virtual registry using linked data sets.
BSAC then shared the list of antimicrobials which will form the initial UKAR study list and proposed data collection fields to seek comments on completeness and feasibility.
Work on building the registry will commence soon and pilot sites from Scotland, England and Wales are being identified. These sites will begin data entry towards the end of 2022 to test the system and processes prior to broader site recruitment in 2023.
The agreed UKAR study list of recently licensed antimicrobials is:
Ceftazidime / avibactam
Ceftolozane / tazobactam
Imipenem / cilastatin / relebactam
Meropenem / vaborbactam